Bioventus (BVS) Share-based Compensation (2021 - 2026)

Bioventus (BVS) has reported Share-based Compensation for 6 consecutive years, with $5.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Share-based Compensation rose 38.37% year-over-year to $5.0 million; the trailing twelve-month figure through Jun 2026 stood at $14.9 million (up 41.24% YoY), and the FY2025 full-year result was $12.7 million, down 4.53% from the prior year.
• Share-based Compensation climbed to $5.0 million in Q2 2026 per BVS's latest filing, from $3.3 million in the prior quarter.
• Across five years, Share-based Compensation topped out at $5.8 million in Q2 2024 and bottomed at -$2.7 million in Q3 2023.
• Historically, Share-based Compensation has averaged $3.0 million across 5 years, with a median of $3.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 159.19% in 2023, then jumped 311.46% in 2024.
• Over 5 years, Share-based Compensation stood at $3.4 million in 2022, then plunged by 48.28% to $1.8 million in 2023, then grew by 13.58% to $2.0 million in 2024, then soared by 70.63% to $3.4 million in 2025, then jumped by 46.54% to $5.0 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $5.0 million, $3.3 million, and $3.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.